These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20489414)

  • 1. Reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Nicholls SJ; Rydén L
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S1. PubMed ID: 20489414
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy and clinical trials: diabetes and cardiovascular risk.
    Peter R
    Curr Opin Lipidol; 2008 Feb; 19(1):101-3. PubMed ID: 18196995
    [No Abstract]   [Full Text] [Related]  

  • 3. Reducing cardiovascular disease risk in patients with type 2 diabetes: a message from the National Diabetes Education Program.
    Gavin JR; Peterson K; Warren-Boulton E;
    Am Fam Physician; 2003 Oct; 68(8):1569-74. PubMed ID: 14596445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dyslipidemia, diabetes and cardiovascular disease].
    Hansen CN; Jensen TJ; Borch-Johnsen K
    Ugeskr Laeger; 2000 Aug; 162(33):4367-70. PubMed ID: 10962957
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimal diabetes management during medical weight loss for cardiovascular risk reduction.
    Nori Janosz KE; Miller WM; Odom J; Lillystone M; McCullough PA
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):761-75. PubMed ID: 16076284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
    Edelman SV
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to improve diabetes care.
    Bodenheimer T
    Am Fam Physician; 2003 Oct; 68(8):1500, 1503-4, 1506. PubMed ID: 14596438
    [No Abstract]   [Full Text] [Related]  

  • 8. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuating cardiovascular risk factors in patients with type 2 diabetes.
    Garber AJ
    Am Fam Physician; 2000 Dec; 62(12):2633-42, 2645-6. PubMed ID: 11142470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?
    Gerstein HC; Rosenstock J
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):137-54. PubMed ID: 15752926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding type 2 diabetes mellitus and associated cardiovascular disease: linked by insulin resistance.
    Tennyson GE
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S450-9. PubMed ID: 12408408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diabetic, hypertensive heart: epidemiology and mechanisms of a very high-risk situation.
    Franjic B; Marwick TH
    J Hum Hypertens; 2009 Nov; 23(11):709-17. PubMed ID: 19516273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors.
    Harris SB; Lank CN
    Can Fam Physician; 2004 Mar; 50():425-33. PubMed ID: 15318682
    [No Abstract]   [Full Text] [Related]  

  • 14. [Diabetes and hypertension. Results from the ADVANCE study].
    Mehlsen J
    Ugeskr Laeger; 2008 Feb; 170(7):531-2. PubMed ID: 18291082
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of type 2 diabetes mellitus: is it in accordance with the guidelines?
    Chan GC; Ghazali O; Khoo EM
    Med J Malaysia; 2005 Dec; 60(5):578-84. PubMed ID: 16515108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
    Ahmed I; Goldstein BJ
    Mt Sinai J Med; 2006 Sep; 73(5):759-68. PubMed ID: 17008936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing vascular disease risk in the type 2 diabetic patient.
    Brown WV; Goldberg RB; Lopes-Virella M; Reaven P
    J Clin Lipidol; 2011; 5(1):3-11. PubMed ID: 21262501
    [No Abstract]   [Full Text] [Related]  

  • 18. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical factors that influence the cardiovascular morbidity in patients with type II diabetes mellitus.
    Kyriazis I; Mendrinos D; Saridi M
    Eur J Intern Med; 2010 Apr; 21(2):e9. PubMed ID: 20206869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.